

## **Title:** “Molecular Pathways: Next Generation Immunotherapy ”

### **Abstract:**

The genetic and cellular alterations that define cancer provide the immune system with the means to generate T cell responses that recognize and eradicate cancer cells. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of nonself and the prevention of autoimmunity. Emerging clinical data suggest that cancer immunotherapy is likely to become a key part of the clinical management of cancer.

### **Date:**

**16 July 2015  
(Thursday)**

### **Time:**

**12:00 PM to 1:00 PM**

### **Venue:**

**Amphitheatre, Level 2  
Duke-NUS Grad Med School  
8 College Road, S169857**

(Opposite Singapore General  
Hospital, Block 6/7)

### **Host:**

**Rebecca DENT** MSc, MD,  
FRCP (Canada)  
Associate Professor  
Clinical Sciences  
Duke-NUS Graduate Medical  
School Singapore  
Senior Consultant  
Medical Oncology  
National Cancer Centre  
Singapore

**“No registration is required.”**

Any enquiry, please contact:  
Sulastri Kamis ( Tel : 6236 9498)  
Beatrice Tan ( Tel : 6516 7923)

### **Speaker:**



### **Daniel CHEN, MD, PhD**

Cancer Immunotherapy Franchise  
Head, Product Development  
Oncology, Genentech  
Adjunct Faculty in Medical Oncology  
at Stanford University

### **Biography:**

**Daniel S. CHEN, MD, PhD** is the Cancer Immunotherapy Franchise Head in Product Development at Genentech/Roche and Adjunct Faculty in Medical Oncology at Stanford University. Since joining Genentech in 2006, Daniel has focused on the clinical development of anti-angiogenic and immune modulatory targeted therapies in both early and late development, as well as the diagnostic tools to aid their development.